639 filings
Page 3 of 32
8-K
tvqrw4k
7 Nov 22
Alaunos Therapeutics to Present Data Highlighting its hunTRâ„¢ TCR Discovery
8:10am
8-K
e3tvxqgd
30 Sep 22
Other Events
8:00am
8-K
yvtgubnbv41d1pw
21 Sep 22
Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference
8:41am
EFFECT
4i3m7vxld387
8 Sep 22
Notice of effectiveness
12:15am
424B5
9r57hwtesc0m35
7 Sep 22
Prospectus supplement for primary offering
4:16pm
8-K
4tmv4qf84 wc3
6 Sep 22
Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy
8:21am
CORRESP
xkgzd4np8ozs9009ptn
2 Sep 22
Correspondence with SEC
12:00am
8-K
ffa8md6s
24 Aug 22
Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference
4:45pm
UPLOAD
3xruj6
19 Aug 22
Letter from SEC
12:00am
8-K
j68q 7nqxg
15 Aug 22
Alaunos Therapeutics Reports Second Quarter 2022 Financial Results
7:07am
8-K
v50nvyvfyxe3oy
4 Aug 22
Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations
5:13pm
8-K
6utho pjtt
13 Jul 22
Other Events
8:00am
8-K
kq2g2i2chm7md j5z
27 Jun 22
Entry into a Material Definitive Agreement
8:07am
8-K
4owludmwfbu q6teg0qb
17 Jun 22
Material Modifications to Rights of Security Holders
4:31pm
8-K
t3vdor4h5sdceaj1
24 May 22
Regulation FD Disclosure
8:30am
8-K
3b1jqc
16 May 22
Alaunos Therapeutics Reports First Quarter 2022 Financial Results
7:30am